# Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions

> **NCT03036306** · PHASE1 · COMPLETED · sponsor: **ScarX Corp** · enrollment: 24 (actual)

## Conditions studied

- Scarring

## Interventions

- **DRUG:** SCX-001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03036306
- **Lead sponsor:** ScarX Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2017-10-02
- **Final completion:** 2017-10-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03036306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03036306, "Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03036306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*